Takeda Pharmaceutical Co Ltd has a consensus price target of $21.33 based on the ratings of 4 analysts. The high is $24 issued by Cowen & Co. on July 19, 2022. The low is $20 issued by TD Cowen on May 16, 2023. The 3 most-recent analyst ratings were released by TD Cowen, TD Cowen, and B of A Securities on May 16, 2023, April 4, 2023, and March 16, 2023, respectively. With an average price target of $23.33 between TD Cowen, TD Cowen, and B of A Securities, there's an implied 74.65% upside for Takeda Pharmaceutical Co Ltd from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/16/2023 | Buy Now | 49.7% | TD Cowen | Ken Cacciatore | $30 → $20 | Maintains | Outperform | Get Alert |
04/04/2023 | Buy Now | 124.55% | TD Cowen | Ken Cacciatore | $24 → $30 | Maintains | Outperform | Get Alert |
03/16/2023 | Buy Now | 49.7% | B of A Securities | Koichi Mamegano | → $20 | Upgrade | Neutral → Buy | Get Alert |
07/19/2022 | Buy Now | 79.64% | Cowen & Co. | Ken Cacciatore | $21 → $24 | Upgrade | Market Perform → Outperform | Get Alert |
10/07/2021 | Buy Now | — | Morgan Stanley | — | — | Downgrade | Overweight → Equal-Weight | Get Alert |
The latest price target for Takeda Pharmaceutical (NYSE:TAK) was reported by TD Cowen on May 16, 2023. The analyst firm set a price target for $20.00 expecting TAK to rise to within 12 months (a possible 49.70% upside). 0 analyst firms have reported ratings in the last year.
The latest analyst rating for Takeda Pharmaceutical (NYSE:TAK) was provided by TD Cowen, and Takeda Pharmaceutical maintained their outperform rating.
The last upgrade for Takeda Pharmaceutical Co Ltd happened on March 16, 2023 when B of A Securities raised their price target to $20. B of A Securities previously had a neutral for Takeda Pharmaceutical Co Ltd.
The last downgrade for Takeda Pharmaceutical Co Ltd happened on October 7, 2021 when Morgan Stanley changed their price target from N/A to N/A for Takeda Pharmaceutical Co Ltd.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Takeda Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Takeda Pharmaceutical was filed on May 16, 2023 so you should expect the next rating to be made available sometime around May 16, 2024.
While ratings are subjective and will change, the latest Takeda Pharmaceutical (TAK) rating was a maintained with a price target of $30.00 to $20.00. The current price Takeda Pharmaceutical (TAK) is trading at is $13.36, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.